european medicines agency glp-1 vision loss recommendation november 2025 Ozempic has 'very rare' sight side effect, EU drugs regulator finds – POLITICO No Link Between GLP-1 Drugs

The regions large and diverse population presents a significant opportunity for market expansion, especially as awareness of innovative weight loss therapies continues to rise

Investigations into biased agonism, where medications are designed to selectively activate beneficial GLP-1 receptor pathways while minimizing those that cause side effects, could eventually produce GLP-1 medications with significantly reduced dry mouth profiles

Imagine having a built-in defense against happy hour overindulgence

If your organization is actively recruiting in competitive talent markets or is thinking through a parental leave update ahead of open enrollment, that post is worth reading closely

$297/mo for monthly plans GLP-1 agonist 15% (68 weeks) 0.20 mg weekly 2.4 mg weekly Tirzepatide $332 / mo Billed Quarterly, Delivered Quarterly

7KI0: Zhang X, Belousoff MJ, Liang YL, Danev R, Sexton PM, Wootten D